Karen Sheppard

University of Melbourne

Australia

Research Interests

Explore related searches

Professors in Australia Professors in Immunology Immunology professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (5)

Stefano Mangiola

Walter and Eliza Hall Institute of Medical Research

AUSTRALIA

View details

Kortnye Smith

Peter MacCallum Cancer Institute

AUSTRALIA

View details

Vihandha Wickramasinghe

University of Melbourne

AUSTRALIA

View details

Conor Kearney

sir peter maccallum department of oncology university of melbourne melbourne victoria australia

AUSTRALIA

View details

Ola Larsson

Karolinska University Hospital

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Karen Sheppard

Research Interests

Explore related searches

Contact this professor

Articles (10)

Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF<sup>V600</sup> melanoma

Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?

Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma

Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma

Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies.

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).

PRMT5: An Emerging Target for Pancreatic Adenocarcinoma

CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory.

CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAF(V600) Melanoma via a p53 Dependent Pathway

Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma

Collaborators (5)

Stefano Mangiola

Kortnye Smith

Vihandha Wickramasinghe

Conor Kearney

Ola Larsson

Make your next move.